Price$0.13-0.01 (-6.98%)
01:30 PM07:45 PM
News · 26 weeks42-56%
2026-04-192026-10-11
Mix2290d
- Other8(36%)
- SEC Filings7(32%)
- Insider4(18%)
- Earnings2(9%)
- Dividends1(5%)
Latest news
25 items- SECSEC Form 8-K filed by Vivos Therapeutics Inc.8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia TestLITTLETON, Colo., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced that it has entered into a definitive Mutual Stock Purchase and Asset Exchange Agreement to acquire an 11% fully diluted equity interest in SOD Sciences, Inc. and a 50% undivided co-ownership interest in SOD’s proprietary pseudohypoxia early-warning test, in exchange for 12,000 shares of newly created Series C Convert
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth InitiativesLITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other breathing and sleep disorders, today announced execution by management on a restructuring and cost reduction plan aimed at saving an estimated $3.6 million annually, beginning in Q4 2026. Parts of the plan have already been implemented, with additional reductions going into effect October 1, 2026. The primary savings in the plan come from staff reductions, vendor relationship changes, negot
- INSIDERSEC Form 4 filed by Director Sokolow Leonard J4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson Gregg C4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- INSIDERChief Executive Officer Huntsman Ronald Kirk acquired $50,000 worth of Preferred Stock (85,910 units at $0.58) (SEC Form 4)4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- SECAmendment: Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K/A - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Announces Material Debt ReductionLITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced that on August 31, 2026, Vivos entered into twelve exchange agreements with Streeterville Capital, LLC, exchanging $2,861,270 of outstanding principal under its secured promissory note (the "Streeterville Note") for 11,445,080 shares of common stock at an exchange price of $0.25 per share. As previously announced o
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment CenterLITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced the execution of definitive collaboration and operating agreements with South Palm Cardiovascular Associates, LLC ("SPCVA") to support the establishment and operation of a regional Sleep & Airway Medicine Center ("SAMC") in Palm Beach County, Florida. The definitive agreements build on th
- INSIDERPrincipal Accounting Officer Amman Bradford K. was granted 250,000 shares, increasing direct ownership by 312,500% to 250,080 units (SEC Form 4)4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- PRVivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine CentersLITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep disorders, today announced that new OSA patient referrals flowing into its Nevada Sleep & Airway Medicine Centers have increased 212% over the most recent six-week period versus the prior six-week period. Since June 1, the total average weekly number of referrals has risen nearly five-fold and has continued to grow week over week. The Company recently an
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and TreatmentNew Location Expected to More Than Double Annual Revenue Production Capacity to Over $10 Million Official Grand Opening Slated for August 27 in Henderson, Nevada With Prominent Industry Opinion Leaders, Sleep Physicians, Dentists Among Scheduled Attendees LITTLETON, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep disorders, today announced the official Grand Opening of its latest state-of-the-art diagnostic, te
- PRVivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational UpdateQuarter highlighted by steadily increasing patient demand for Vivos’ differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company’’) (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep related breathing disorders, today reported financial results and operating highlights for the three and six months ended June 30, 2026. Kirk Huntsman, Vivos’ Chairman and
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vivos Therapeutics Inc.SCHEDULE 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
- PRVivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference CallLITTLETON, Colo., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company’’) (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep related breathing disorders, announced it plans to release its second quarter 2026 financial results after market close today, Friday, August 14, 2026. The Company will conduct a conference call at 5:00 pm (Eastern Time) to review the results and provide operational updates. Vivos encourages investors and other interested parties to join its conference
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue OperationsGreenway analysis estimates AI-enabled automation in Nevada alone could create up to $9.0 million in potential annual value, including approximately $8.0 million from increased patient capacity and $1.0 million from revenue-cycle improvements In addition, Vivos expects to save $1.8 million annually from Greenway’s recovery of an estimated 46,000+ employee hours, while creating capacity for nearly 30,000 additional patient visits LITTLETON, Colo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalitie
- PRVivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device TechnologyLITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep related breathing disorders, today announced that the United States Patent and Trademark Office has issued US Patent No. 12,697,190 "Vibrational Oral Appliance with Mandibular Advancements" (the "’190 Patent"), a continuation of the Company’s previously issued US Patent No. 12,048,608 (the "’608 Patent"), issued July 30, 2024. Taken together, these two p
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- INSIDERSEC Form 4 filed by Large owner Skaff Michael C4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- INSIDERSEC Form 3 filed by new insider V-Co Investors 4 Llc3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
VVOS FAQ
7 questionsWhat does Vivos Therapeutics Inc. do?
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States...Where does VVOS stock trade?
Vivos Therapeutics Inc. (VVOS) is listed on NASDAQ.What sector and industry is VVOS in?
Vivos Therapeutics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Vivos Therapeutics Inc. go public?
Vivos Therapeutics Inc. (VVOS) completed its IPO in 2020.What are analysts saying about VVOS?
Vivos Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $1000.00 price target on 2021-08-13. Recent price targets cluster around $1000.00.What companies are similar to VVOS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare VVOS side-by-side with any of them on Quantisnow.How can I track VVOS on Quantisnow?
Quantisnow aggregates Vivos Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VVOS to receive live email and push alerts on every new disclosure.